Oral probiotics and topical hydrocortisone may reduce severity of Psoriasis

Written By :  Jacinthlyn Sylvia
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-11-27 14:30 GMT   |   Update On 2022-11-27 14:30 GMT
Advertisement

Psoriasis area severity index (PASI), Dermatology life quality index (DLQI), and visual analogue scale (VAS) was improved in psoriasis patients who received oral probiotics with topical hydrocortisone. The findings of the study were published in the Journal of Dermatology Research and Practice.

There has been a recent increase with regard to the oral administration of probiotics for the treatment of psoriasis. Oral probiotics have been known (previous research) to have a positive role in the treatment of psoriasis. Since the anti-inflammatory effect of the branded preprobiotics, Lactocare® on the severity of ulcerative colitis and also on the serum electrolytes and trace elements in psoriasis has previously been published, this study by Ali Akbarzadeh and peers aimed to evaluate the effect of oral probiotic on the treatment of psoriasis.

Advertisement

A total of 52 patients with psoriasis were randomly divided into treatment and placebo (control) groups. The control group received topical hydrocortisone along with placebo, whereas in the treatment group, Lactocare® was orally administrated along with hydrocortisone.

The findings of this study were:

  • The mean value of VAS, DLQI, and PSAI were recorded and evaluated as pretreatment and post-treatment in both groups for a period of 3 months.
  • The mean of the values in the control groups were compared to the values in the treatment group.
  • Intragroup analysis was done comparing the mean of the scores at baseline 4-weeks, 8-weeks, and 12-weeks post-treatment .
  • A significant reduction was noticed in the PASI, VAS, and DLQI scores 12 weeks post-treatment in the treatment group when compared to the control group.

Source:

Akbarzadeh, A., Alirezaei, P., Doosti-Irani, A., Mehrpooya, M., & Nouri, F. (2022). The Efficacy of Lactocare® Synbiotic on the Clinical Symptoms in Patients with Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. In C. G. Burkhart (Ed.), Dermatology Research and Practice (Vol. 2022, pp. 1–7). Hindawi Limited. https://doi.org/10.1155/2022/4549134

Tags:    
Article Source : Hindawi

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News